双时相门冬胰岛素50治疗2型糖尿病的安全性和有效性

Review of the effectiveness and safety of biphasic insulin aspart 50

预混门冬胰岛素50含有50%的速效门冬胰岛素和50%的中效鱼精蛋白结合门冬胰岛素,在药代动力学上比预混人胰岛素50R起效更快,达峰浓度更高。因此,其除了有效降低血糖外,还能改善餐后血糖,具有低血糖风险较小,且重度和夜间低血糖发生率低的特点。预混门冬胰岛素紧邻餐时注射,使用灵活方便,当用于简单强化治疗时,与基础-餐时治疗方案有效性和安全性相当。预混门冬胰岛素50为糖尿病患者,尤其是餐后血糖偏高的患者提供了新选择。

Biphasic insulin aspart 50 （BIAsp50） is a premixed formulation containing 50% insulin aspart for rapid action and 50% protamine-retarded insulin aspart for intermediate action. Compared with premix human insulin 50, the pharmaeokinetics of BIAsp50 showed a faster onset and a higher peak of insulin concentration. Therefore, BIAsp50 is effective to decrease plasma glucose, and to significantly improve postprandial plasma glucose, with low risk of hypoglycaemia, particularly major and nocturnal hypoglycaemia. Intensified treatment with BIAsp50 showed a comparable effectiveness and safety with basal-bolus regimen. BIAsp50, injected immediately before meal, is flexible and convenient, and is a new option for the patients with diabetes, especially those with postprandial hyperglycaemia.